Just Prior to Leadership Change, FDA Announces Public Workshops to Advance Dialogues on HCT Product Development and Optimizing Pregnancy Registries

January 21, 2025

Reading Time : 2 min

In the final stretch of the Biden administration, the Food and Drug Administration (FDA) laid the groundwork for continued engagement with the public on two challenging areas of product development, each of which is of high interest to patients, clinical communities, industry stakeholders and policy-makers in Congress.

The FDA is pressing forward on supporting human cell therapies and tissue-based product development. On January 17, 2025, the FDA issued a notice in the Federal Register announcing a virtual public workshop entitled “Cell Therapies and Tissue-Based Products: A Public Workshop on Generating Scientific Evidence to Facilitate Development” to fulfill Section 3205 of the Food and Drug Omnibus Reform Act of 2022 (P.L. 117-328), which required the FDA to hold a public workshop to discuss the best practices on generating scientific data necessary to further facilitate the development of certain human cell-, tissue- and cellular-based medical products (HCT/P).

The FDA’s HCT/P workshop is scheduled to be held on February 25, 2025, and topics to be discussed during the workshop include (1) the current state of the science for tissue and cell-derived therapies and explore what challenges remain as the field continues to mature; (2) nonclinical work to assess the safety of cell therapy products in support of product development; (3) considerations for characterization of cell therapy products to help ensure manufacturing quality during product development and through commercialization; (4) clinical considerations and future directions for locally administered cell therapies under investigation for niche indications; and (5) considerations for a revised risk-based HCT/P framework. The deadline for submitting comments on this workshop is March 18, 2025.

In addition, by announcing a public workshop on optimizing pregnancy registries, the FDA is focusing on another challenging areas of product development while also pursuing a Prescription Drug User Fee Act (PDUFA) commitment. In the most recent reauthorization of PDUFA commitment letter, the FDA agreed to develop a framework describing how to use data optimally from different types of post-approval pregnancy safety studies. On January 17, 2025, the FDA issued a notice announcing a public workshop entitled “Optimizing Pregnancy Registries” to be held on March 27 and 28. This public workshop is being held in collaboration with the University of Maryland Center of Excellence in Regulatory Science and Innovation program.

The purpose of the public workshop is to discuss challenges in designing and implementing pregnancy registries and consider innovative approaches to improve the design and conduct of pregnancy registries. In announcing the workshop, the FDA announced the it will discuss the current status of pregnancy registries and challenges in gathering data regarding the safety of drug and biological products used during pregnancy, perspectives from interested parties (FDA, academia, industry, health care providers and patients) on strategies to improve the design and conduct of pregnancy registries, and innovative approaches/models to facilitate the conduct of pregnancy registries, including disease-based multi-product, multi-sponsor pregnancy registries.

Both of these public workshops provide opportunities for stakeholders to engage with the FDA on areas of product development for patients and also demonstrate how the agency’s perpetual work on behalf of patients and public health spans administrations.

Share This Insight

Previous Entries

Eye on FDA

July 25, 2025

On July 25, the U.S. Food and Drug Administration (FDA), in collaboration with the U.S. Department of Health and Human Services (HHS) and U.S. Department of Agriculture (USDA), unveiled the highly anticipated joint request for information on ultra-processed foods (UPFs). Specifically, the administration is seeking information and data to help develop a uniform definition for UPFs in the U.S. food supply.

...

Read More

Eye on FDA

July 22, 2025

Dr. George Tidmarsh has been selected to replace Dr. Jacqueline Corrigan-Curay as the director of the Center for Drug Evaluation and Research (CDER) at FDA as she prepares to retire from the agency. Dr. Tidmarsh is an adjunct professor of pediatrics and neonatology at Stanford University and is credited as having been involved in the development of several approved drugs. Until late May of this year, Dr. Tidmarsh was a member of the board of directors of Revelation Biosciences, a company engaged in developing an anti-inflammatory IV therapy. Among other roles and experiences he has had, he was a founding Co-Director of Stanford’s Master of Science in Translational Research and Applied Medicine (M-TRAM) program, and founded Horizon Pharma in 2005.

...

Read More

Eye on FDA

July 16, 2025

Recently, it was reported that the U.S. Food and Drug Administration (FDA) is launching two cross-agency artificial intelligence (AI) councils. One AI council will be tasked with addressing how the agency uses AI internally and the other will focus on policy governing AI’s use in FDA-regulated products (reportedly pre-existing AI councils in various FDA divisions will continue to operate) (Politico Pro).

...

Read More

Eye on FDA

July 16, 2025

This week, the U.S. Food and Drug Administration (FDA) granted another color additive petition, approving the use of Gardenia (Genipin) in various food and beverage products. This marks the fourth naturally-derived color additive authorized for use in foods since FDA’s April announcement to phase out all petroleum-based synthetic dyes in food and transition to natural alternatives (read more here). Gardenia blue, derived from the fruit of the gardenia, a flowering evergreen, is now approved for use in sport drinks, flavored or enhanced non-carbonated water, fruit drinks and ades, ready-to-drink teas, hard candy and soft candy.

...

Read More

Eye on FDA

July 10, 2025

This morning, the U.S. Food and Drug Administration (FDA) announced the publication of more than 200 decision letters, also known as complete response letters (CRLs), with plans to release more from the archives. The CRLs released today are associated with applications for drugs and biologics submitted for approval between 2020 and 2024 that have since been approved by the agency.

...

Read More

Eye on FDA

June 26, 2025

On June 24, 2025, in a hearing before the U.S. House of Representatives Committee on Energy and Commerce, the Secretary of Health and Human Services (HHS), Robert F. Kennedy Jr. revealed that his department plans to soon launch an advertising campaign encouraging Americans to use wearable health devices. The campaign is set to be “one of the biggest advertising campaigns in HHS history.”

...

Read More

Eye on FDA

June 20, 2025

On June 17, 2025, the U.S. Food and Drug Administration (FDA) announced the Commissioner’s National Priority Voucher (CNPV) program, a new program that aims to speed up drug application review for companies aligned with U.S. national priorities. In terms of qualifying for the program, the key differentiator between this program and other “priority” review programs is that the application must support increased domestic drug manufacturing—presumably meaning that the applicant commits to manufacture the drug in the United States. The key benefit is that drug developers can redeem the vouchers to accelerate their application review time from 10-12 months to one to two months after a sponsor’s final drug application submission. The program includes enhanced communication with the sponsor and will utilize a team-based review process, in which a multidisciplinary team of FDA experts, who will prereview clinical information, gather for a one-day “tumor board style” meeting. While some of the review work is envisioned to be “front loaded” before the actual application is submitted, it is still the case that a two-month review window would be a radical acceleration of the review timeline compared to standard review times.

...

Read More

Eye on FDA

June 16, 2025

Last week, the U.S. Food and Drug Administration (FDA) released two educational videos and a supplemental fact sheet to guide dietary supplement manufacturers and distributors through the New Dietary Ingredient Notification (NDIN) review process. Under Section 413 of the Federal Food, Drug, and Cosmetic Act, manufacturers and distributors must submit an NDIN to notify FDA before marketing a dietary supplement with a new dietary ingredient. These resources offer guidance on structuring submissions and outline what to expect during the agency’s review. Ultimately, they are intended to enhance the quality of NDIN submissions and minimize common pitfalls, with the goal of avoiding delays or unfavorable results in the agency’s review.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.